ES2529144R1 - Combinacion de aad para uso en el tratamiento del vhc - Google Patents

Combinacion de aad para uso en el tratamiento del vhc Download PDF

Info

Publication number
ES2529144R1
ES2529144R1 ES201490005A ES201490005A ES2529144R1 ES 2529144 R1 ES2529144 R1 ES 2529144R1 ES 201490005 A ES201490005 A ES 201490005A ES 201490005 A ES201490005 A ES 201490005A ES 2529144 R1 ES2529144 R1 ES 2529144R1
Authority
ES
Spain
Prior art keywords
adb
combination
hcv treatment
hcv
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201490005A
Other languages
English (en)
Other versions
ES2529144A2 (es
ES2529144B1 (es
Inventor
Barry M Bernstein
Rajeev M Menon
Amit Khatri
Sven Mensing
Sandeep Dutta
Daniel E Cohen
Thomas J Podsadecki
Scott C Brun
Walid M Awni
Emily O Dumas
Cheri E Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority claimed from PCT/US2012/061085 external-priority patent/WO2013059638A1/en
Publication of ES2529144A2 publication Critical patent/ES2529144A2/es
Publication of ES2529144R1 publication Critical patent/ES2529144R1/es
Application granted granted Critical
Publication of ES2529144B1 publication Critical patent/ES2529144B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES201490005A 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc Expired - Fee Related ES2529144B1 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201161055036P 2011-10-21 2011-10-21
US61/55036 2011-10-21
US201161056217P 2011-11-21 2011-11-21
US61/56217 2011-11-21
US201261058719P 2012-01-17 2012-01-17
US61/58719 2012-01-17
US201261060046P 2012-02-17 2012-02-17
US61/60046 2012-02-17
US201261061988P 2012-04-03 2012-04-03
US61/61988 2012-04-03
US201261065625P 2012-06-06 2012-06-06
US61/65625 2012-06-06
US201261071179P 2012-10-10 2012-10-10
US61/71179 2012-10-10
PCT/US2012/061085 WO2013059638A1 (en) 2011-10-21 2012-10-19 Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv

Publications (3)

Publication Number Publication Date
ES2529144A2 ES2529144A2 (es) 2015-02-17
ES2529144R1 true ES2529144R1 (es) 2015-03-10
ES2529144B1 ES2529144B1 (es) 2015-10-26

Family

ID=52465028

Family Applications (3)

Application Number Title Priority Date Filing Date
ES201431521A Withdrawn - After Issue ES2572355B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc
ES201490005A Expired - Fee Related ES2529144B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc
ES201431520A Withdrawn - After Issue ES2572330B1 (es) 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES201431521A Withdrawn - After Issue ES2572355B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES201431520A Withdrawn - After Issue ES2572330B1 (es) 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc

Country Status (1)

Country Link
ES (3) ES2572355B1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118080C2 (uk) * 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
CN104771364B (zh) * 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GERMAN POLINA et al. Lack of a Clinically Significant Pharmacokinetic Drug-Drug Interaction between Sofosbuvir (GS-7977) and GS-5885 or GS-9669 in Healthy Volunteers.Hepatology, 20121001 John Wiley & Sons, Inc, USA 01/10/2012 VOL: 56 No: Suppl.1 Pags: 1072A - 1073A ISSN 0270-9139, resumen *
JAZWINSKI A B et al. Direct-acting antiviral medications for chronic hepatitis C virus infection.Gastroenterology and Hepatology 2011 Gastro-Hep Communications, Inc. usa 00/03/2011 VOL: 7 No: 3 Pags: 154 - 162 ISSN 1554-7914 (print), tabla 1, página 160-161. *
MEMBRENO F E et al. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors.CLINICS IN LIVER DISEASE, 20110801 SAUNDERS, PHILADELPHIA, PA, US 01/08/2011 VOL: 15 No: 3 Pags: 611 - 626 ISSN 1089-3261, tabla 1, página 615-616. *
MURAKAMI E et al. Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977.Journal of Biological Chemistry, 20101105 American Society for Biochemistry and Molecular Biology 05/11/2010 VOL: 285 No: 45 Pags: 34337 - 34347 ISSN 0021-9258 Doi: doi:10.1074/jbc.M110.161802, página 34337. *
VACHON M -L et al. The era of direct-acting antivirals has begun: The beginning of the end for HCV?.Seminars in Liver Disease 2011 Thieme Medical Publishers, Inc. usa 00/00/2011 VOL: 31 No: 4 Pags: 399 - 409 ISSN 0272-8087 (print) ISSN 1098-8971 (electronic) Doi: doi:10.1055/s-0031-1297928, tabla 2, página 406. *

Also Published As

Publication number Publication date
ES2572330R1 (es) 2016-11-03
ES2529144A2 (es) 2015-02-17
ES2572355A2 (es) 2016-05-31
ES2572355B1 (es) 2017-08-24
ES2572330B1 (es) 2017-08-24
ES2572330A2 (es) 2016-05-31
ES2529144B1 (es) 2015-10-26
ES2572355R1 (es) 2016-11-03

Similar Documents

Publication Publication Date Title
CR20140177A (es) Métodos para el tratamiento de vhc
CO7000768A2 (es) Diacilhidrazina cristalina y el uso de la misma
EP2739857A4 (en) FAN
ES1140631Y (es) Generador accionado por el viento y dispositivo de bloqueo del impulsor para generador accionado por el viento
LT2726092T (lt) Sulieti serpino polipeptidai ir jų panaudojimo būdai
CO6811867A2 (es) Cannabinoides para uso en el tratamiento del dolor neuropático
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
CO6940391A2 (es) Transportador de cinta y procedimiento para su funcionamiento y su uso
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
BR112014005406A2 (pt) composição de vacina e respectivo uso
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
EP2735243A4 (en) BRAIDED LOCKING STRIP
BR112014010432A2 (pt) uso médico
BR112013034010A2 (pt) aparelho para uso em secagem de grão
FR2987739B1 (fr) Ceinture de soutien lombaire
ITTO20131062A1 (it) Procedimento per ridurre i danni provocati da organismi dannosi in coltivazioni di mais
IL228729A0 (en) Treatment regimens
CO6801770A2 (es) Uso de secnidazol en el tratamiento de infecciones dentales
HRP20171385T1 (hr) Kombinacije s peptidom s cikliziranom okosnicom
BR112013022474A2 (pt) aparelho de derivação para tanque de absorção
BR112014011288A2 (pt) dispositivo de estiramento
ES1073946Y (es) Dispositivo para el pesaje de personas
ES2529144R1 (es) Combinacion de aad para uso en el tratamiento del vhc
PL2776132T3 (pl) Urządzenie do obróbki powietrza

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2529144

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151026

FD2A Announcement of lapse in spain

Effective date: 20210915